NASDAQ:NGNE Neurogene Q1 2025 Earnings Report $16.98 -0.22 (-1.28%) Closing price 04:00 PM EasternExtended Trading$17.06 +0.08 (+0.47%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Neurogene EPS ResultsActual EPS-$1.08Consensus EPS -$1.05Beat/MissMissed by -$0.03One Year Ago EPSN/ANeurogene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeurogene Announcement DetailsQuarterQ1 2025Date5/9/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time7:30AM ETUpcoming EarningsNeurogene's Q3 2025 earnings is scheduled for Monday, November 17, 2025, with a conference call scheduled on Tuesday, November 18, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Neurogene Earnings HeadlinesAnalysts Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $46.17September 21 at 3:11 AM | americanbankingnews.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | businesswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 22 at 2:00 AM | American Alternative (Ad)Neurogene Advances NGN-401 Gene Therapy for Rett SyndromeAugust 14, 2025 | theglobeandmail.comNeurogene Inc. Reports Increased Losses Amid R&D FocusAugust 11, 2025 | tipranks.comNeurogene Reports Second Quarter 2025 Financial Results and Highlights Recent UpdatesAugust 11, 2025 | businesswire.comSee More Neurogene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email. Email Address About NeurogeneNeurogene (NASDAQ:NGNE), Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions. Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances. Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.View Neurogene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
